SEARCH

SEARCH BY CITATION

References

  • 1
    Brandjes DP, Heijboer H, Büller HR, De Rijk M, Jagt H, Ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 14859.
  • 2
    Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2: 5158.
  • 3
    Gustafsson D, Nyström J-E, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K-J, Ungell A-L, Sörensen H, Nâgârd S, Abrahamsson A, Bylund R. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 17181.
  • 4
    Eriksson UG, Johansson L, Frison L, Bredberg U, Gustafsson D. Single and repeated oral dosing of H 376/95, a prodrug of the direct thrombin inhibitor melagatran, to young healthy male subjects. Blood 1999; 94 (Suppl. 1): 26a.
  • 5
    Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S, Karlsson O, Nilsson A, Sörensen H. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 1108.
  • 6
    Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78: 128692.
  • 7
    Johansson LC, Eriksson UG, Frison L, Fager G. Pharmacokinetics of H 376/95 in young and elderly healthy subjects. Blood 2000; 96 (11): 57a.
  • 8
    Eriksson UG, Johansson L, Taure K, Frison L, Bredberg U, Gustafsson D. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor H 376/95 in healthy male subjects. Haemostasis 2000; 30 (Suppl. 1): 164.
  • 9
    Sarich TC, Eriksson UG, Mattsson C, Wolzt M, Frison L, Fager G, Gustafsson D. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 2002; 87: 3005.
  • 10
    Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hägg A, Jonsson T, Lapidus L, Leijd B, Stockelberg D, Säfwenberg U, Taghavi A, Thorsén M. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999; 81: 35863.
  • 11
    Eriksson BI, Lindbratt S, Kälebo P, Bylock A, Frison L, Welin L, Dahl O, Gustafsson D. METHRO II. Dose response study of the novel oral, direct thrombin inhibitor, H 376/95 and its subcutaneous formulation melagatran, compared with dalteparin as thromboembolic prophylaxis after total hip or knee replacement. Haemostasis 2000; 30 (Suppl. 1): 201.
  • 12
    Marder VJ, Soulen RL, Atichartakarn VBudzynski AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 101829.
  • 13
    Schiele F, Lindgaerde F, Eriksson H, Bassand JP, Wallmark A, Hansson PO, Grollier G, Sjo M, Moia M, Camez A, Smyth V, Walker M. Subcutaneous recombinant Hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomised trial. International Multicentre Hirudin Study. Thromb Haemost 1997; 77: 8348.
  • 14
    Bounameaux H, Ehringer H, Hulting J, Rasche H, Rapold HJ, Zultak M, and the ADVENT Trial. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (Napsagatran, Ro 46–6204) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis. Results from the European Multicentre ADVENT Trial. Thromb Haemost 1997; 78: 9971002.
  • 15
    Parent F, Bridey F, Dreyfus M, Musset D, Grimon G, Duroux P, Meyer D, Simonneau G. Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost 1993; 70: 3868.
  • 16
    Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Soria J, Soria C, Camez A, Mirshahi MC, Bassand JP. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71: 55862.
  • 17
    Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. Lancet 1960; 1: 130912.
  • 18
    Hull RD, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 8558.
  • 19
    Schulman S. Anticoagulation in venous thrombosis. JR Soc Med 1996; 89: 62430.
  • 20
    Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 97582.
  • 21
    Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 67781.
  • 22
    Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, Van Der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334: 6827.
  • 23
    The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 65762.
  • 24
    The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. A phase II evaluation. Circulation 2000; 102: 272631.
  • 25
    Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001; 344: 62631.
  • 26
    Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Buller HR. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thromb Haemost 2000; 83: 6526.
  • 27
    Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 167681.
  • 28
    Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999; 94: 18797.
  • 29
    Eriksson-Lepkowska M, Thuresson A, Bylock A, Frison L, Eriksson UG. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics and pharmacodynamics of diclofenac in healthy male volunteers. Thromb Haemost 2001; 86 (Suppl.) P786 (Abstr.)
  • 30
    Eriksson-Lepkowska M, Thuresson A, Bylock A, Frison L, Eriksson UG. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics of diazepam in healthy male volunteers. Thromb Haemost 2001; 86 (Suppl.) P785 (Abstr.)
  • 31
    Johansson S, Bylock A, Eriksson-Lepkowska M, Thuresson A, Frison L, Eriksson UG. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics of nifedipine, in healthy male volunteers. Thromb Haemost 2001; 86 (Suppl.) P784 (Abstr.)